muscle function

Abcuro takes $200M series C to fund KLRG1 antibody pivotal trial

Abcuro has secured the series C funds to power its anti-KLRG1 antibody through a phase 2/3 muscle disease trial ahead of a planned push to regulators.

James Waldron Feb 12, 2025 8:30am

weight loss scale weigh measure tape obesity overweight

Lilly, BioAge to test muscle regeneration drug with tirzepatide

Oct 26, 2023 11:39am

Chasing Big Pharma rivals, NMD posts data on rare disease drug

Oct 11, 2022 6:48am

Aeon hits phase 2 goals in rare disorder

Sep 23, 2022 11:30am

Astellas quietly cuts $450M-plus Cytokinetics R&D pact

May 3, 2021 7:15am

Dyne Therapeutics gunning for $100M IPO weeks after a VC raise

Aug 26, 2020 7:55am